Cancer R&D 2024 has wrapped up successfully. We’re grateful for your interest and interaction with Alfa Cytology. We’re eager to continue providing our expertise in cancer drug development. Let’s look back on these memorable moments!

Learn More
Banner

CD39 Inhibitor Development for Pancreatic Cancer

CD39 Inhibitor Development for Pancreatic Cancer

With cutting-edge technology and extensive expertise, Alfa Cytology focuses on preclinical research of pancreatic cancer. Our service aims to decipher the intricate role of CD39 in pancreatic cancer progression and devise innovative strategies to inhibit its activity.

Introduction to CD39 and Its Signaling Pathway

CD39, also known as ectonucleoside triphosphate diphosphohydrolase 1 (ENTPD1), is a typical ectonucleotidase with a catalytic site on the extracellular face. This glycoprotein consists of two transmembrane domains, an extracellular catalytic domain, and several glycosylation sites that are crucial for its stability and function. These domains are critical for the nucleotide hydrolysis process, and its primary function involves the conversion of extracellular ATP and ADP into AMP, ensuring precise regulation of extracellular nucleotide concentrations, which regulates purinergic signaling and modulating immune responses.

Fig. 1 Pathway and function of NTRK gene.Fig. 1 Therapeutic regimens targeting CD39 alone or in combination with other strategies enhance antitumor immunity. (Guo S, et al, 2022)

CD39 Inhibitor Development for Pancreatic Cancer

Many tumors deplete immunostimulatory eATP by increasing CD39 expression to evade immune surveillance. Studies have shown that CD39 expression levels are increased in various tumors, including pancreatic cancer. CD39 inhibitors are therapeutic agents designed to block the activity of the enzyme CD39 and have therapeutic potential for diseases characterized by adenosine overproduction and immunosuppression, such as chronic infections and autoimmune diseases. CD39 inhibitors are currently being explored as potential treatments for pancreatic cancers with several promising candidates progressing through various stages of the drug development pipeline. Here are some examples:

CD39 Inhibitor Molecular Type Phase
TIDAL-01 (TTX-030) Monoclonal antibody
AB680 Small molecule inhibitor
SRF617 Monoclonal antibody
BAY 1905254 Small molecule inhibitor

Our Services

Alpha Cytology offers a comprehensive, customized service focused on the complex mechanisms of CD39-mediated immune evasion, with the aim of delivering potent inhibitors that have the potential to revolutionize the treatment of pancreatic cancer. Our expertise spans the spectrum from molecular characterization to functional testing, ensuring a robust pipeline for the discovery and validation of CD39 inhibitors.

Molecule Types for CD39 Inhibitor Development

Alfa Cytology offers comprehensive CD39 inhibitor development services for pancreatic cancer covering a wide range of molecule types, notably the following:

Small Molecule Inhibitors

These inhibitors are designed to bind to the active site of CD39, blocking its enzymatic activity and preventing the conversion of ATP/ADP to AMP.

Monoclonal Antibodies (mAbs)

These are designed to bind to specific epitopes on CD39, blocking its activity or marking it for destruction by the immune system.

Antibody Fragments

These contain Fab, scFv, and single-domain antibodies(sdAbs) that retain the ability to specifically bind to CD39. They offer advantages in terms of tissue penetration and reduced immunogenicity.

Peptide-Based Inhibitors

These include synthetic and mimetic peptides that mimic natural substrates or regulatory proteins, bind to CD39 and block its function.

CD39 Inhibitor Development Process

Target Identification and Validation

This step involves pinpointing CD39 as a target using genomic, proteomic, and bioinformatics approaches to understand its role in pancreatic cancer.

CD39 Inhibitor Design and Optimization

This phase focuses on refining the structure of identified inhibitors using computational modeling and medicinal chemistry to enhance their potency and selectivity.

Drug Screening

Identify potential CD39 inhibitors from libraries of small molecules, monoclonal antibodies, antibody fragments, siRNAs, miRNAs, and peptides by using high-throughput screening methods.

Preclinical Evaluation

Comprehensive preclinical evaluation using in vivo and in vitro models for antitumor efficacy, DMPK/ADME, and safety testing of CD39 inhibitors.

Why Choose Us?

Tailored Solutions

Advanced Technology

Professional Expertise

Collaborative Approach

Alfa Cytology is your partner of choice for groundbreaking preclinical research in pancreatic cancer. Focusing on CD39 inhibitors and other pancreatic cancer therapeutic targets, our services help researchers precisely target and develop highly specific and effective therapies to advance the field of precision oncology. With our extensive experience and state-of-the-art methodologies, we offer a comprehensive range of customized services to accelerate your R&D efforts. For inquiries or to learn more about how we can support your research project, please contact us.

Reference

  1. Guo S, et al. CD39–A bright target for cancer immunotherapy. Biomedicine & Pharmacotherapy. 2022, 151: 113066.
All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.